



MUTANT ACE2 PROTEINS AND METHODS OF USING SAME

WARF: P210188W001

Inventors: Philip Romero, Peter Heinzelman

The Invention

UW-Madison researchers have identified novel ACE2 mutants having enhanced activity and/or specificity in hydrolyzing angiotensin II. ACE2 (angiotensin converting enzyme 2) is a key metalloprotease of the renin angiotensin system (RAS). Given ACE2's role as a counter regulator to the ACE/Ang-II/AT1 receptor axis in the RAS, it has anti-inflammatory effects. As a result, soluble and recombinant forms of ACE2 have been developed to treat several diseases, including acute pulmonary and cardiac conditions, as well as fibrotic and oncologic disease. The mutants identified by the inventors have the potential for enhanced or altered activity, which could lead to improved treatments.

Additional Information

For More Information About the Inventors

- [Philip Romero](#)

Tech Fields

- [Drug Discovery & Development : Other drug discovery & development](#)
- [Therapeutics & Vaccines : Other therapeutic technologies](#)

For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854